Your session is about to expire
← Back to Search
Arm 1: I-ASA 100mg, then C-ASA 162mg tablet for Healthy Subjects
Study Summary
This trial will compare two aspirin treatments to measure safety, effectiveness & how they are absorbed.
- Healthy Subjects
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has the Food and Drug Administration cleared Arm 2: C-ASA 162mg tablet, then I-ASA 100mg for public use?
"Taking into account the Phase 1 status of Arm 2: C-ASA 162mg tablet, then I-ASA 100mg, our team at Power judged its safety to be a 1 due to sparse evidence in favour of efficacy and safety."
Are there any specific eligibility requirements for participants in this trial?
"To qualify, applicants must meet the criteria of healthy subjects and be between 18-55 years old. This trial is currently seeking 88 participants in total."
How many participants are currently included in this clinical experiment?
"Accurate. Clinicaltrials.gov reveals that this medical experiment, which posted on October 14th 2022, is still recruiting patients. Currently 88 individuals are required to participate at 2 locations worldwide."
Does this research trial include minors under the age of 18?
"The age limits for this medical trial are 18 and 55 respectively, as stated by the inclusion criteria."
Is this experiment currently in search of participants?
"Affirmative. The clinicaltrials.gov website reveals that this experiment, which was first announced on October 14th 2022, is actively recruiting subjects. About 88 people are expected to participate at 2 test centres."
Share this study with friends
Copy Link
Messenger